Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

By Tedeschi Alessandra   Montillo Marco   Strocchi Elena   Cafro Anna   Tresoldi Elisabetta   Intropido Liliana   Nichelatti Michele   Marbello Laura   Baratè Claudia   Camaggi Carlo   Morra Enrica  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 771-779

Springer Publishing Company

Access to resources Recommend Favorite

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

By Smith Sonali M.  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1405-1410

Informa Healthcare

Access to resources Recommend Favorite

Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody

By              

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2603-2608

Spandidos Publications

Access to resources Recommend Favorite

Ara-C increases gastric cancer cell invasion by upregulating CD-147-MMP-2/MMP9 via the ERK signaling pathway

By                    

Oncology Reports, Vol. 33, Iss. 4, 2015-01 ,pp. : 2045-2051

Spandidos Publications

Access to resources Recommend Favorite